Peculiarities of Microbiota in Patients with Inflammatory Intestinal Diseases
- Authors: Sukhina M.A.1,2, Yudin S.M.2, Zagainova A.V.2, Makarov V.V.2, Veselov A.V.1, Anosov I.S.1, Lyagina I.A.1, Chistyakova D.A.1, Safin A.L.1, Shelygin Y.A.1
-
Affiliations:
- National Medical Research Centre for Coloproctology named after A.N. Ryzhikh
- Centre for Strategic Planning and Management of Biomedical Health Risks
- Issue: Vol 77, No 3 (2022)
- Pages: 165-171
- Section: GASTROENTEROLOGY: CURRENT ISSUES
- URL: https://ogarev-online.ru/vramn/article/view/125586
- DOI: https://doi.org/10.15690/vramn1480
- ID: 125586
Cite item
Full Text
Abstract
Background. The intestinal microbiota, on the one hand, protects a person from pathogens, on the other hand, it itself may be one of the triggers and/or mediators of progression in inflammatory bowel diseases. Inflammatory bowel disease (IBD) predominantly affects young people of working age. It noted a steady increase in the incidence of IBD in recent decades throughout the world and in Russia. Inflammatory bowel diseases significantly affect quality of life and lead to complications of having to perform surgery, which significantly reduces the quality of life. Aims — of the study was to investigate the composition of the microbiota of the colon, the search features of the microbial spectrum of patients with inflammatory bowel disease patients compared with control patients. Materials and methods. A prospective study was carried out between patients with inflammatory bowel disease and patients without inflammatory bowel disease for the period 2018–2019. The study included 157 IBD patients and 150 patients without IBD. All patients studied stool, which have been subjected to microbiological and metagenomic study. Results. Most often, facultative anaerobic microorganisms were present in the stool of patients with IBD (in 60%, 103–109 CFU/g) and in patients without IBD (69%, 103–109 CFU/g), the share of gram-negative bacteria accounted for 52%, in mostly represented by bacilli belonging to the order Enterobacteriales, only 7% of isolated gram-negative facultative aerobic microorganisms were gram-negative non-fermenting bacteria represented by 5 genera: Acinetobacter, Burkholderia, Pseudomonas, Stenotrophomonas, Ralstonia. Gram-positive facultative anaerobic microorganisms in 89% were represented by cocci of the genus Enterococcus, Streptococcus, Staphylococcus, Micrococcus, Gemella, Globicatella, Granulicatella. Conclusions. According to the results of our study, special attention should be paid to the presence of rare microaerophilic and obligate anaerobic microorganisms in the fecal microbiota of patients with IBD (Arcobacter butzleri, Gardnerella vaginalis, Aromatoleum aromaticum, Terrisporobacter glycolicus (Clostridium glycolicum), Solobacterium moorei, Alloscardovia omnicolens, Fusobacterium nucleatum, Fusobacterium ulcerans, Dialister micraerophilus), that have not been isolated from patients without IBD. A timely adequate assessment of the composition and functional characteristics of the microbiota in terms of key biomarkers will make it possible to carry out targeted diagnostics and prevention of the immediate and long-term consequences of inflammatory bowel diseases.
Full Text
##article.viewOnOriginalSite##About the authors
Marina A. Sukhina
National Medical Research Centre for Coloproctology named after A.N. Ryzhikh; Centre for Strategic Planning and Management of Biomedical Health Risks
Author for correspondence.
Email: marinamari272015@gmail.com
ORCID iD: 0000-0003-4795-0751
SPIN-code: 9577-5290
Scopus Author ID: 57192270856
ResearcherId: AAH-3311-2020
PhD in Biology
Russian Federation, Moscow; MoscowSergei M. Yudin
Centre for Strategic Planning and Management of Biomedical Health Risks
Email: yudin@cspmz.ru
ORCID iD: 0000-0003-2199-8474
SPIN-code: 9706-5936
MD, PhD, Professor
Russian Federation, MoscowAngelika V. Zagainova
Centre for Strategic Planning and Management of Biomedical Health Risks
Email: angelikaangel@mail.ru
ORCID iD: 0000-0003-4772-9686
SPIN-code: 6642-7819
Scopus Author ID: 12772760200
PhD in Biology
Russian Federation, MoscowValentin V. Makarov
Centre for Strategic Planning and Management of Biomedical Health Risks
Email: makarov@cspmz.ru
ORCID iD: 0000-0002-1907-0098
PhD in Biology
Russian Federation, MoscowAlexei V. Veselov
National Medical Research Centre for Coloproctology named after A.N. Ryzhikh
Email: a_veselov82@mail.ru
ORCID iD: 0000-0003-3115-1787
SPIN-code: 9333-8673
MD, PhD
Russian Federation, MoscowIvan S. Anosov
National Medical Research Centre for Coloproctology named after A.N. Ryzhikh
Email: ivaansv@yandex.ru
ORCID iD: 0000-0002-9015-2600
SPIN-code: 4062-6344
MD, PhD
Russian Federation, MoscowIrina A. Lyagina
National Medical Research Centre for Coloproctology named after A.N. Ryzhikh
Email: lyagina59@mail.ru
ORCID iD: 0000-0001-5434-9062
Russian Federation, Moscow
Daria A. Chistyakova
National Medical Research Centre for Coloproctology named after A.N. Ryzhikh
Email: mushka1994@list.ru
ORCID iD: 0000-0002-2486-081X
SPIN-code: 7628-3590
Russian Federation, Moscow
Anton L. Safin
National Medical Research Centre for Coloproctology named after A.N. Ryzhikh
Email: antonyz@rambler.ru
ORCID iD: 0000-0001-8013-3863
SPIN-code: 9418-0508
MD, PhD
Russian Federation, MoscowYuri A. Shelygin
National Medical Research Centre for Coloproctology named after A.N. Ryzhikh
Email: info@gnck.ru
ORCID iD: 0000-0002-8480-9362
SPIN-code: 7989-8228
MD, PhD, Professor, Academician of the RAS
Russian Federation, MoscowReferences
- Khalif IL, Shapina MV. Inflammatory bowel disease treatment in Eastern Europe: current status, challenges and needs. Curr Opin Gastroenterol. 2017;33(4):230–233. doi: https://doi.org/10.1097/MOG.0000000000000370
- Belousova E, Khalif I. Tu1290 Social, Demographic and Clinical Features of Inflammatory Bowel Disease in Russia. Gastroenterology. 2012;142(5):S–794. doi: https://doi.org/10.1016/s0016-5085(12)63083-2
- Lynch SV, Pedersen O. The Human Intestinal Microbiome in Health and Disease. N Engl J Med. 2016;375(24):2369–2379. doi: https://doi.org/10.1056/NEJMra1600266
- Littman DR, Pamer EG. Role of the commensal microbiota in normal and pathogenic host immune responses. Cell Host Microbe. 2011;10(4):311–323. doi: https://doi.org/10.1016/j.chom.2011.10.004
- Nishida A, Inoue R, Inatomi O, et al. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11(1):1–10. doi: https://doi.org/10.1007/s12328-017-0813-5
- Yu LC-H. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis. J Biomed Sci. 2018;25(1):79. doi: https://doi.org/10.1186/s12929-018-0483-8
- Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 2007;104(34):13780–13785. doi: https://doi.org/10.1073/pnas.0706625104
- Gophna U, Sommerfeld K, Gophna S, et al. Differences between Tissue-Associated Intestinal Microfloras of Patients with Crohn’s Disease and Ulcerative Colitis. J Clin Microbiol. 2006;44(11):4136–4141. doi: https://doi.org/10.1128/jcm.01004-06
- El Mouzan M. Fecal microbiota profile in newly-diagnosed crohn disease in children: data from a middle eastern population. Morressier; 2016. doi: https://doi.org/10.26226/morressier.57d034d1d462b80292383670
- Kostic AD, Xavier RJ, Gevers D. The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead. Gastroenterology. 2014;146(6):1489–1499. doi: https://doi.org/10.1053/j.gastro.2014.02.009
- Kang S, Im J. Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives. Gut. 2011;60(5):631–637. doi: https://doi.org/10.1136/gut.2010.223263
- Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA. 2008;105(43):16731–16736. doi: https://doi.org/10.1073/pnas.0804812105
- Round J, Mazmanian S. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9(5):313–323. doi: https://doi.org/10.1038/nri2515
- Biedermann L, Rogler G. The intestinal microbiota: its role in health and disease. Eur J Pediatr. 2015;174(2):151–167. doi: https://doi.org/10.1007/s00431-014-2476-2
- Azad MAK, Sarker M, Li T, et al. Probiotic Species in the Modulation of Gut Microbiota: An Overview. Biomed Res Int. 2018;2018:9478630. doi: https://doi.org/10.1155/2018/9478630
- Mazmanian S, Round J, Kasper D. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature. 2008;453(7195):620–625. doi: https://doi.org/10.1038/nature07008
- Sheehan D, Moran C, Shanahan F. The microbiota in inflammatory bowel disease. J Gastroenterol. 2015;50(5):495–507. doi: https://doi.org/10.1007/s00535-015-1064-1
- Бухарин О.В., Перунова Н.Б. Микросимбиоценоз. — Екатеринбург: УрО РАН, 2014. [Buharin OV, Perunova NB. Mikrosimbiocenoz. Ekaterinburg: UrO RAN; 2014. (In Russ.)]
- Бухарин О.В., Перунова Н.Б. Симбиотические взаимоотношения человека и микроорганизмов // Физиология человека. — 2012. — Т. 38. — № 1. — С. 128–138. [Buharin OV, Perunova NB. Simbioticheskie vzaimootnosheniya cheloveka i mikroorganizmov // Fiziologiya cheloveka. 2012;38(1):128–138. (In Russ.)]
- Nagao-Kitamoto H, Kamada N. Host-microbial Cross-talk in Inflammatory Bowel Disease. Immune Netw. 2017;17(1):1–12. doi: https://doi.org/10.4110/in.2017.17.1.1
- Schirmer M, Garner A, Vlamakis H, et al. Microbial genes and pathways in inflammatory bowel disease. Nat Rev Microbiol. 2019;17(8):497–511. doi: https://doi.org/10.1038/s41579-019-0213-6
- Colquhoun C, Duncan M, Grant G. Inflammatory Bowel Diseases: Host-Microbial-Environmental Interactions in Dysbiosis. Diseases. 2020;8(2):13. doi: https://doi.org/10.3390/diseases8020013
- Alam M, Amos G, Murphy A, et al. Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels. Gut Pathog. 2020;12:1. doi: https://doi.org/10.1186/s13099-019-0341-6
- Vijay A, Valdes AM. Role of the gut microbiome in chronic diseases: a narrative review. Eur J Clin Nutr. 2022;76(4):489–501. doi: https://doi.org/10.1038/s41430-021-00991-6
- Шендеров Б.А. Медицинская и микробная экология и функциональное питание: в 3 т. Т. 3: Пробиотики и функциональное питание. — М.: ГРАНТЪ, 2001. — 286 с. [Shenderov BA. Medicinskaya i mikrobnaya ekologiya i funkcional’noe pitanie: v 3 t. T. 3: Probiotiki i funkcional’noe pitanie M.: GRANT; 2001. 286 s. (In Russ.)]
Supplementary files
